More than 22 published human clinical trials using MenaQ7 Vitamin K2 as MK-7 have confirmed safe and efficacious heart and bone benefits. Some of those trials examined the positive impact of K2 supplementation in patients with compromised kidney health as those patients expressed intense calcification as a symptom of their condition.

A new trial published in the American Journal of Transplantation has echoed this positive impact. According to the researchers, “in this randomized, double-blind, placebo-controlled clinical trial, vitamin K- supplementation did not alter serum calcification propensity, but ‘inhibited’ progression of arterial stiffness in kidney transplant recipients, suggesting that vitamin K may have vascular effects independent of serum calcification propensity. These results provide a basis for long-term intervention studies with vitamin K2-supplementation in kidney transplant recipients.”

March is National Kidney Month Gnosis by Lesaffre is excited to see these results, picking up on some of the important work that started with MenaQ7 Vitamin K2 as MK-7. Westenfeld et al. published a standout randomized controlled trial in 2013, that confirmed most hemodialysis patients have a functional vitamin K deficiency, and that K2 supplementation (as MenaQ7) induced a dose- and time-dependent decrease in circulating inactive Matrix Gla Protein (MGP) and Osteocalcin, the K-dependent proteins that support heart and bone health, respectively.

We will continue to explore the potential of Vitamin K2 to improve global health through scientific research. And we hope those efforts will confirm that a natural vitamin can meet the needs of healthy and patient populations.